New look at myocardial infarction: Toward a better aspirin

Cardiovascular Research

Volumn 43, Issue 1, 1999, Pages 25-31

  Bing, Richard J ^a   Yamamoto, Tadahiko ^a   Yamamoto, Masako ^a   Kakar, Rani ^a   Cohen, Anna ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Aspirin; Myocardial infarction; Nitric oxide; NO donor; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; THROMBOXANE A2;

CARDIOVASCULAR RISK; DRUG ACTIVITY; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE; INFLAMMATORY CELL; MACROPHAGE FUNCTION; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG COMBINATIONS; DRUG DESIGN; EPOPROSTENOL; HUMANS; MACROPHAGES; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE; THROMBOXANE A2;

EID: 0032994636     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00074-7     Document Type: Review

References (65)

1. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. J Am Med Assoc. 59:1912;2015-2020.
2. Lee T.H., Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Recommendations bases on a quantitative analysis. Ann Intern Med. 105:1986;221-233.
3. Katus H.A., Remppis A., Neumann F.J., et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation. 83:1991;902-912.
4. McCluskey E.R., Corr P.B., Lee B.I., Saffitz J.E., Needlman P. The arachidonic acid metabolic capacity of canine myocardium is increased during healing of acute myocardial infarction. Circ Res. 51:1982;743-750.
5. Dudek R.R., Wildhirt S., Conforto A., et al. Inducible nitric oxide synthase activity in myocardium after myocardial infarction in rabbit. Biochem Biophys Res Commun. 205:1994;1671-1680.
6. Bing R.J., Suzuki H. Myocardial infarction and nitric oxide. Mol Cell Biochem. 160:1996;303-306.
7. Kimura A., Roseto J., Suh K., Cohen A.M., Bing R.J. Effect of acetylsalicylic acid on nitric oxide production in infarcted heart in situ. Biochem Biophys Res Commun. 251:1998;874-878.
8. Cirino G., Wheeler-Jones C.P.D., Wallace J.L., Del Soldato P., Baydoun A.R. Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal sparing properties. Br J Pharmacol. 117:1996;1421-1426.
9. Minuz P., Lechi C., Zuliani V., Gaino S., Tommasoli R., Lechi A. NO-aspirins: antithrombotic activity of derivatives of acetylsalicylic acid releasing nitric oxide. Cardiovasc Drug Rev. 16:1998;31-47.
10. Johnson G., Tsao P.S., Lefer A.M. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med. 19:1991;244-252.
11. Woolfson R.G., Patel V.C., Neild G.H., Yellon D.M. Inhibition of nitric oxide synthesis reduces infarct size by an adenosin-dependent mechanism. Circulation. 91:1995;1545-1551.
12. Node K., Kitakaze M., Kosaka H., et al. Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation. 93:1996;356-364.
13. Franchi A.M., Chaud M., Rettori V., Suburo A., McCann S.M., Gimeno M. Role of nitric oxide in eicosanoid synthesis and uterine motility in estrogen-treated rat uteri. Proc Natl Acad Sci USA. 91:1994;539-543.
14. Tetsuka T., Daphna-Iken D., Srivastava S.K., Baier L.D., DuMaine J., Morrison A.R. Cross-talk between cyclooxygenase and nitric oxide pathways: Prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci USA. 91:1994;12168-12172.
15. Davidge S.T., Baker A.N., McLaughlin M.K., Roberts J.M. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res. 77:1995;274-283.
16. Salvemini D., Settle S.I., Masferrer J.L., Seibert K., Currie M.G., Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Clin Pharmacol. 114:1995;1171-1178.
17. Kanematsu M., Ikeda K., Yamada Y. Interaction between nitric oxide synthase and cyclooxygenase pathway in osteoblastic MC3T3-E1 cells. J Bone Miner Res. 12:1997;1789-1796.
18. Wallace J.L., McKnight W., Soldato P.D., Baydoun A.R., Birino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest. 96:1995;2711-2718.
19. Pabla R., Curtis M.J. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res. 77:1995;984-992.
20. Coker S.J., Ledinghan I.M., Parratt J.R., Zeitlin I.J. Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Br J Pharmacol. 72:1981;593-595.
21. Hibbs J.B., Taintor R.R., Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 235:1987;473-476.
22. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA. 87:1990;682-685.
23. Xie Q.W., Cho H.J., Calaycay J., et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 256:1992;225-228.
24. Rapoport R.M., Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res. 52:1983;352-357.
25. 2+-independent nitric oxide synthase in the myocardium. J Pharmacol. 105:1992;575-580.
26. Suzuki H., Wolf W.P., Akiyama K., et al. Effect of inhibitors of inducible form of nitric oxide synthase in infarcted heart muscle. Proc Assoc Am Physicians. 108:1996;173-178.
27. Kimura A., Roseto J., Suh K., Bing R.J. Dexamethasone on inducible nitric oxide synthase and nitrite/nitrate production in myocardial infarction. Proc Soc Experiment Biol Med. 219:1998;138-143.
28. Wagner D.A., Tannenbaum S.R. Enhancement of nitrate biosynthesis by Escherichia cell lipopolysaccharide. Magee P.N. Banbury Report 12: Nitrosamine and Cancer. 1982;437-443 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
29. Stuehr D.J., Gross S.S., Sakuma I., Levi R., Nathan C.F. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med. 169:1989;1011-1020.
30. Marletta M., Yoon P.S., Lyengar R., Leaf C.D., Wishnok J.S. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry. 27:1988;8706-8711.
31. 3, in plasma after experimental myocardial infarction. J Mol Cell Cardiol. 29:1997;1-9.
32. Akiyama K., Kimura A., Suzuki H., et al. Production of oxidative products of nitric oxide in infarcted human heart. J Am Coll Cardiol. 32:1998;373-379.
33. Stuehr D.J., Nathan C.F. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 169:1989;1543-1555.
34. Berger H.J., Zaret B.L., Speroff L., Cohen L.S., Wolfson S. Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs. Circ Res. 38:1976;566-571.
35. Yamamoto T, Yamamoto M, Cohen AM, Kakar R, Bing RJ. 1998:in press.
36. Isakson P.D., Raz A., Denny S.E., Pure E., Deeleman P. A novel prostaglandin is the major product of arachidonic acid metabolism in rabbit heart. Proc Natl Acad Sci USA. 74:1977;101-105.
37. deDeckere E.A.M., Nugteren D.H., TenHoor F. Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature. 268:1977;160-163.
38. Block A.J., Poole S., Vane J. Modification of basal release of prostaglandins from rabbit isolated hearts. Prostaglandins. 7:1974;473-485.
39. Salvemini D., Currie M.G., Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest. 97:1996;2562-2568.
40. Rettori V., Gimeno M., Lyson K., McCann S.M. Nitric oxide mediates norepinephrine-induced prostaglandin E2 release from the hypothalamus. Proc Natl Acad Sci USA. 89:1992;11543-11546.
41. Salvemini D., Misko T.P., Masferrer J.L., Seibert K., Currie M.C., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA. 90:1993;7240-7244.
42. Kalyanaraman B., Mason R.P., Tainer B., Eling T.E. The free radical formed during the hydroperoxide-mediated deactivation of ram seminal vesicles is hemoprotein-derived. J Biol Chem. 257:1982;4764-4768.
43. Fuster V., Dyken M.L., Vokonas P.S., Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 87:1993;659-675.
44. Böger R.H., Bode-Böger S.M., Gutzki F.M., Tsikaf D., Weskott H.P., Frolich J.C. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low-dose aspirin in men. Clin Sci. 84:1993;517-524.
45. Vane J. Towards a better aspirin. Nature. 367:1994;215-216.
46. Schoemaker R.G., Saxena P.R., Kalkman E.A. Low-dose aspirin improves in vivo hemodynamics in conscious chronically infarcted rats. Cardiovasc Res. 37:1998;108-114.
47. Kalkman E.A.J., van Suylen R.-J., van Dijk J.P.M., Saxena P.R., Schoemaker R.G. Aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in rat. J Mol Cell Cardiol. 27:1995;2483-2494.
48. Bonow R.O., Lipson L.L., Shehan F.H., et al. Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol. 47:1981;258-264.
49. Möbert J., Becker B.F. Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J Am Coll Cardiol. 31:1998;1687-1694.
50. Ritter J.M., Cockcroft J.R., Doktor H.S., Beacham J., Barrow S.E. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. Br J Clin Pharmacol. 28:1989;573-579.
51. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Garner C., Seibert K., Marnett L.J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science. 280:1998;1268-1270.
52. Ljusegren M.E., Axelsson K.L. Lactate accumulation in isolated hypoxic rat ventricular myocardium: effect of different modulators of the cyclic GMP system. Pharmacol Toxicol. 72:1993;56-60.
53. Richard V., Blan C.T., Kaeffer N., Tron C., Thuillez C. Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischemia and reperfusion in rats: role of nitric oxide. Br J Pharmacol. 115:1995;1532-1538.
54. Schulz R., Panas D.L., Catena R., Moncada S., Olley P.M., Lopashuk G.D. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumor necrosis factor-alpha. Br J pharmacol. 114:1995;27-34.
55. Patel V.C., Yellon D.M., Singh K.J., Neild G.H., Woolfson R.G. Inhibition of nitric oxide limits infarct size in the in situ rabbit heart. Biochem Biophys Res Commun. 194:1993;234-238.
56. Marks G.S., Mclaughlin B.E., Jimmo S.L., Poklenska-Koziel M., Brien J.F., Nakatsu K. Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine but not by glyceryl trinitrate. Drug Metab Dispos. 23:1995;1248-1252.
57. Feelisch M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparations and handling of aqueous NO solutions. J Cardiovasc Pharmacol. 17:1991;S25-S33.
58. MacAllister R.J., Calver A.L., Riezebos J., Collier J., Vallance P. Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther. 273:1995;154-160.
59. Kankaanranta H., Rydell E., Petersson A.-S., Holm P., et al. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br J Pharm. 117:1996;401-406.
60. Szekeres M., Dézsi D., Monos E., Metsä-Ketelä T. Effect of a new nitric oxide donor on the biomechanical performance of the isolated ischaemic rat heart. Acta Physiol Scand. 161:1997;55-61.
61. Foucher-Lavergne A., Kolsky H., Spreux-Varoquaux O., Delonca J., Beaufils P.H. Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction. J Cardiovasc Pharmacol. 22:1993;779-784.
62. Willerson J.T., Cohen L.S., Maseri A. Coronary artery disease: pathophysiology and clinical recognition. Willerson J.T., Cohn J.N. Cardiovascular Medicine. 1995;333-365 Churchill Livingstone, New York.
63. Ryan T.J., Anderson J.L., Antman E.M., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. Circulation. 94:1996;2341-2350.
64. Node K., Kitakaze M., Kosaka H., Minamino T., Funaya H., Hori M. Amelioration of ischemia-and reperfusion-induced myocardial injury by 17β-estradiol. Circulation. 96:1997;1953-1963.
65. Boissel J.-P. Individualizing aspirin therapy for prevention of cardiovascular events. J Am Med Assoc. 280:1998;1949-1950.